Keros Therapeutics Inc. (KROS) is a clinical-stage biopharmaceutical company headquartered in Lexington, Massachusetts, USA. The company is focused on developing therapies for the treatment of rare diseases caused by protein dysregulation.
Keros' lead product candidate is KER-050, a monoclonal antibody designed to inhibit the activity of fibroblast growth factor receptor 2 (FGFR2) alpha, which is involved in the development and progression of multiple diseases. KER-050 is being evaluated in a Phase 2 clinical trial for the treatment of patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Keros is also developing other product candidates for the treatment of various rare diseases, including KER-047, a therapeutic candidate for the treatment of patients with anemia related to rare genetic disorders.
In November 2021, Keros announced that it had entered into a collaboration agreement with Eli Lilly and Company to develop novel therapies for the treatment of various diseases. Under the terms of the agreement, Keros will receive an upfront payment and is eligible to receive additional milestone payments and royalties based on the achievement of certain development, regulatory, and commercial milestones.
As of September 30, 2021, Keros had cash, cash equivalents, and marketable securities of $239.2 million. The company has incurred significant research and development expenses as it continues to advance its pipeline of product candidates.
Keros' stock is listed on the NASDAQ stock exchange and has a market capitalization of approximately $632 million as of February 21, 2023. The stock has experienced significant volatility in recent years and investors should carefully consider the risks associated with investing in a clinical-stage biopharmaceutical company.
|
